Unibest

Pharmaceutical intermediates

AVACOPAN Intermediates

5 pharmaceutical intermediates for AVACOPAN. Indication: Antineutrophil cytoplasmic antibody-associated vasculitis; Wegener's granulomatosis; microscopic polyangiitis.

提交项目All intermediates

About AVACOPAN

Originator
Chemocentryx Inc
Indication
Antineutrophil cytoplasmic antibody-associated vasculitis; Wegener's granulomatosis; microscopic polyangiitis
Approved Date
10/07/2021
NCE Patent
10/07/2026
DS/DP
12/21/2029

Available intermediates

5 intermediates currently listed for AVACOPAN. Request specifications, documentation or a quotation for any item below.

AVACOPAN intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Ethyl (2R,3S)-2-(4-(cyclopentylamino)phenyl)piperidine-3-carboxylate bis((2R,3R)-2,3-bis((4-methylbenzoyl)oxy)succinate)1893415-79-6 //
(2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid1346623-11-7//
tert-butyl 3-(4-nitrophenyl)-3-oxopropanoate142550-25-2//
Ethyl 4-nitrobenzoylacetate838-57-3//
Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with ethyl (2R,3S)-2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-3-piperidinecarboxylate (1:1)1357259-88-1//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward AVACOPAN?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →